Influx Health. — 360° view

Influx Health, a company in the Pharmaceuticals industry, reported revenue of ₹85 crore and net profit of ₹12 crore for the September 2026 quarter.

Influx Health. (NSE: INFLUX-SM) closed at ₹285.00 on 20 Nov 2026, up 20.6% over the past year. Its market capitalisation is ₹660 crore and it trades at 29.2 times earnings.

Share price
₹285.00 (20 Nov 2026)
Market cap
₹660 Cr (20 Nov 2026)
P/E
29.21 (20 Nov 2026)
Revenue
₹85 Cr (September 2026 quarter)
Net profit
₹12 Cr (September 2026 quarter)
ROCE
38.4% (FY26)
ROE
27.9% (FY26)
Book value
₹48.7 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹315.00 / ₹183.05 (20 Nov 2026)
1-year return
20.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: INFLUX-SM

Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.